IXICO Presents New Huntington's Disease Research

IXICO plc

29 October 2026

 

IXICO plc

(“IXICO”, the “Company” or the “Group”)

IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data

29 October 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces the presentation of new research in Huntington’s Disease (HD) at the latest European Huntington’s Disease Network (EHDN) Clinical Research Congress 2026.

The research evaluated a novel method designed to reduce unwanted differences in HD patient brain volume measurement data collected using different MRI scanners, equipment and clinical sites. The findings highlighted the importance of validating imaging analysis methods and preserving clinically relevant information when analysing brain imaging data, rather than assuming that reducing measurement variabilities always improves the ability to accurately track disease progression.

The research was conducted using the Huntington’s Disease Imaging Harmonisation (HD-IH) consortium data set.  IXICO is a founding member of the HD-IH, a collaboration with leading biopharmaceutical companies and the CHDI Foundation. Through its proprietary AI-powered IXI™ platform, IXICO has analysed more than 6,000 MRI scans from over 2,000 participants, generating valuable insights into HD disease progression and advancing the development and validation of imaging biomarkers.

A summary of the research is available IXICO’s website on the Scientific Publications page.

Robin Wolz, Chief Scientific Officer of IXICO, commented: “In Huntington’s clinical trials, researchers measure changes in brain structures to monitor disease progression. However, differences between MRI scanners and clinical sites can introduce variability into these measurements, potentially making it harder to detect genuine disease-related changes.  Our findings demonstrate the importance of ensuring that imaging biomarkers reliably capture meaningful changes in disease progression. This research reinforces IXICO’s position in Huntington’s disease and our commitment to advancing the science that underpins more effective clinical trials and the development of new treatments for patients.”

Ends

For further information please contact:

IXICO plc	[phone]
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	[phone]
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.  

The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s.  Image data is interrogated by the platform and IXICO’s expert scientists translating complex data into clinically meaningful insights while minimizing data variability and increasing reproducibility.

 

END